Exercise for sarcopenia in older people: a systematic review and network meta-analysis

Key points

1. 01Resistance exercise alone had the largest effect on quality of life (SMD 1.11, high certainty) compared to usual care.
2. 02Combining resistance and balance exercise was the most effective approach for improving gait speed (MD 0.16 m/s, moderate certainty), likely exceeding the minimally important difference of 0.1 m/s.
3. 03Adding nutrition to exercise improved handgrip strength more than exercise alone; resistance plus nutrition reached an MD of 3.93 kg (high certainty), approaching the 5 kg minimally important difference.
4. 04For the timed up and go test, resistance and balance exercise was intermediately effective (MD -1.85 s, moderate certainty), though the confidence interval crossed the 2.1 s minimally important difference threshold.
5. 05Multicomponent exercise (resistance, aerobic, balance plus nutrition) did not prevent muscle or strength decline over 36 months in a large trial, suggesting early targeted intervention may be needed.

How it was conducted

Design

Systematic review and frequentist random-effects network meta-analysis of RCTs

Participants

3728 older adults with sarcopenia; median age 72.9 years; 73.3% female

Included studies

42 RCTs identified from 5988 screened citations; median follow-up 12 weeks

Comparators

Multiple exercise types (resistance, aerobic, balance, combinations) with or without nutrition vs. usual care

Primary outcomes

Quality of life, handgrip strength, usual gait speed, timed up and go test, five-repetition chair stand test, all-cause mortality

Evidence grading

GRADE framework applied to rate certainty as high, moderate, low, or very low

What they found

• Resistance exercise alone vs. usual care for quality of life: SMD 1.11 (95% CI 0.54 to 1.68), high certainty.
• Resistance and aerobic and balance exercise vs. usual care for quality of life: SMD 0.68 (95% CI 0.32 to 1.04), moderate certainty.
• Resistance plus nutrition for handgrip strength: MD 3.93 kg (95% CI 2.22 to 5.65), high certainty (MID 5 kg).
• Resistance and balance plus nutrition for handgrip strength: MD 4.19 kg (95% CI 2.55 to 5.83), moderate certainty.
• Resistance and balance exercise for usual gait speed: MD 0.16 m/s (95% CI 0.08 to 0.24), moderate certainty (MID 0.10 m/s).
• Resistance exercise alone for usual gait speed: MD 0.11 m/s (95% CI 0.04 to 0.18), moderate certainty.
• Resistance and balance exercise for timed up and go test: MD -1.85 s (95% CI -3.22 to -0.49), moderate certainty (MID 2.1 s).
• Resistance and aerobic plus nutrition for five-repetition chair stand test: MD -2.28 s (95% CI -3.73 to -0.83), high certainty (MID 2.3 s).
• All-cause mortality (1 RCT, 1205 participants): RR 1.23 (95% CI 0.74 to 2.06), moderate certainty; no statistically significant difference.
• Falls in multicomponent intervention group vs. control: 13.2% vs. 8.2%, RR 1.62 (95% CI 1.16 to 2.27).
• Any adverse event rate: 55.7% intervention vs. 49.5% control, RR 1.13 (95% CI 1.01 to 1.25).

Limitations

• Only one RCT reported mortality and adverse event data, limiting conclusions on these critical outcomes.
• Inconsistent definitions of sarcopenia across trials and heterogeneous participant comorbidities reduce comparability.
• Many intervention-specific comparisons were based on few studies or indirect estimates, lowering confidence in rankings.
• Subgroup effects for sex and setting were rated as low credibility; grey literature was not searched.

Why it matters

For patients

Older adults with sarcopenia can expect meaningful improvements in quality of life and walking speed from resistance exercise, especially when combined with balance training and nutritional support.

For clinicians

Resistance exercise combined with balance training is the best-evidenced prescription for physical function; adding protein or comprehensive nutrition boosts handgrip gains beyond exercise alone.

For readers

This network meta-analysis provides moderate-to-high certainty rankings of exercise types, filling a key evidence gap for clinical guideline development on sarcopenia management.